Physician profile
Jason Mark Bailey
NPI 1568887255
$2,280.80
in general payments reported to CMS, 2019-2025
29 companies · $809 in 2025
The $809 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $285 · 2021: $70.30 · 2022: $116 · 2023: $323 · 2024: $185 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276 · Education: $35.06 · Travel and Lodging: $6.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,275.78 |
| Education | $35.06 |
| Travel and Lodging | $6.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $558.19 | 2019-2025 | Ams 800 Artificial Urinary Sphincter, Axonics, Advance Xp |
| Astellas Pharma US INC | $401.31 | 2019-2023 | Myrbetriq |
| Teleflex LLC | $178.89 | 2021-2025 | Urolift, Barrigel |
| Neotract INC. | $112.24 | 2020 | |
| Cook Medical LLC | $104.49 | 2019 | |
| Janssen Biotech, INC. | $102.15 | 2024-2025 | Erleada |
| Urogen Pharma, INC. | $94.71 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $76.48 | 2023-2024 | Gemtesa, Orgovyx |
| Coloplast Corp | $74.18 | 2020-2025 | |
| Axonics, INC. | $69.07 | 2022-2024 | Axonics |
| Vertex Pharmaceuticals Incorporated | $59.62 | 2024-2025 | |
| Laborie Medical Technologies Corp. | $53.81 | 2023 | |
| Ferring Pharmaceuticals INC. | $52.96 | 2025 | Adstiladrin |
| Olympus America INC. | $52.82 | 2025 | Cysto-Nephro Videoscope, Itind System |
| Endo USA, INC. | $43.00 | 2025 | Xiaflex |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $35.06 | 2025 | Imfinzi |
| Amgen INC. | $26.43 | 2019 | |
| Travere Therapeutics, INC. | $24.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.57 | 2024 | |
| Myriad Genetic Laboratories, INC. | $17.11 | 2023 | Prolaris |
| Civco Medical Instruments | $17.09 | 2025 | |
| Becton, Dickinson and Company | $14.92 | 2022 | |
| Pfizer INC. | $14.90 | 2024 | |
| Abbvie INC. | $14.61 | 2024 | |
| Photocure INC | $14.46 | 2023 | Cysview |
| Davol INC. | $13.16 | 2023 | |
| Progenics Pharmaceuticals, INC. | $13.04 | 2023 | Pylarify |
| Urovant Sciences INC | $12.18 | 2022 | |
| Intuitive Surgical, INC. | $6.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.